Penetrance estimates for <it>BRCA1 </it>and <it>BRCA2 </it>based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family

<p>Abstract</p> <p>Background</p> <p>The identification of a <it>BRCA1 </it>or <it>BRCA2 </it>mutation in familial breast cancer kindreds allows genetic testing of at risk relatives. However, considerable controversy exists regarding the cancer r...

Full description

Bibliographic Details
Main Authors: Lalloo Fiona, Woodward Emma, Shenton Andrew, Evans D Gareth, Howell Anthony, Maher Eamonn R
Format: Article
Language:English
Published: BMC 2008-05-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/8/155
id doaj-dba714ce2fc74787a5cf7eae88e40763
record_format Article
spelling doaj-dba714ce2fc74787a5cf7eae88e407632020-11-24T23:51:18ZengBMCBMC Cancer1471-24072008-05-018115510.1186/1471-2407-8-155Penetrance estimates for <it>BRCA1 </it>and <it>BRCA2 </it>based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the familyLalloo FionaWoodward EmmaShenton AndrewEvans D GarethHowell AnthonyMaher Eamonn R<p>Abstract</p> <p>Background</p> <p>The identification of a <it>BRCA1 </it>or <it>BRCA2 </it>mutation in familial breast cancer kindreds allows genetic testing of at risk relatives. However, considerable controversy exists regarding the cancer risks in women who test positive for the family mutation.</p> <p>Methods</p> <p>We reviewed 385 unrelated families (223 with <it>BRCA1 </it>and 162 with <it>BRCA2 </it>mutations) ascertained through two regional cancer genetics services. We estimated the penetrance for both breast and ovarian cancer in female mutation carriers (904 proven mutation carriers – 1442 females in total assumed to carry the mutation) and also assessed the effect on penetrance of mutation position and birth cohort.</p> <p>Results</p> <p>Breast cancer penetrance to 70 and to 80 years was 68% (95%CI 64.7–71.3%) and 79.5% (95%CI 75.5–83.5%) respectively for <it>BRCA1 </it>and 75% (95%CI 71.7–78.3%) and 88% (95%CI 85.3–91.7%) for <it>BRCA2</it>. Ovarian cancer risk to 70 and to 80 years was 60% (95%CI 65–71%) and 65% (95%CI 75–84%) for <it>BRCA1 </it>and 30% (95%CI 25.5–34.5%) and 37% (95%CI 31.5–42.5%) for <it>BRCA2</it>. These risks were borne out by a prospective study of cancer in the families and genetic testing of unaffected relatives. We also found evidence of a strong cohort effect with women born after 1940 having a cumulative risk of 22% for breast cancer by 40 years of age compared to 8% in women born before 1930 (p = 0.0005).</p> <p>Conclusion</p> <p>In high-risk families, selected in a genetics service setting, women who test positive for the familial <it>BRCA1/BRCA2 </it>mutation are likely to have cumulative breast cancer risks in keeping with the estimates obtained originally from large families. This is particularly true for women born after 1940.</p> http://www.biomedcentral.com/1471-2407/8/155
collection DOAJ
language English
format Article
sources DOAJ
author Lalloo Fiona
Woodward Emma
Shenton Andrew
Evans D Gareth
Howell Anthony
Maher Eamonn R
spellingShingle Lalloo Fiona
Woodward Emma
Shenton Andrew
Evans D Gareth
Howell Anthony
Maher Eamonn R
Penetrance estimates for <it>BRCA1 </it>and <it>BRCA2 </it>based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family
BMC Cancer
author_facet Lalloo Fiona
Woodward Emma
Shenton Andrew
Evans D Gareth
Howell Anthony
Maher Eamonn R
author_sort Lalloo Fiona
title Penetrance estimates for <it>BRCA1 </it>and <it>BRCA2 </it>based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family
title_short Penetrance estimates for <it>BRCA1 </it>and <it>BRCA2 </it>based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family
title_full Penetrance estimates for <it>BRCA1 </it>and <it>BRCA2 </it>based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family
title_fullStr Penetrance estimates for <it>BRCA1 </it>and <it>BRCA2 </it>based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family
title_full_unstemmed Penetrance estimates for <it>BRCA1 </it>and <it>BRCA2 </it>based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family
title_sort penetrance estimates for <it>brca1 </it>and <it>brca2 </it>based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family
publisher BMC
series BMC Cancer
issn 1471-2407
publishDate 2008-05-01
description <p>Abstract</p> <p>Background</p> <p>The identification of a <it>BRCA1 </it>or <it>BRCA2 </it>mutation in familial breast cancer kindreds allows genetic testing of at risk relatives. However, considerable controversy exists regarding the cancer risks in women who test positive for the family mutation.</p> <p>Methods</p> <p>We reviewed 385 unrelated families (223 with <it>BRCA1 </it>and 162 with <it>BRCA2 </it>mutations) ascertained through two regional cancer genetics services. We estimated the penetrance for both breast and ovarian cancer in female mutation carriers (904 proven mutation carriers – 1442 females in total assumed to carry the mutation) and also assessed the effect on penetrance of mutation position and birth cohort.</p> <p>Results</p> <p>Breast cancer penetrance to 70 and to 80 years was 68% (95%CI 64.7–71.3%) and 79.5% (95%CI 75.5–83.5%) respectively for <it>BRCA1 </it>and 75% (95%CI 71.7–78.3%) and 88% (95%CI 85.3–91.7%) for <it>BRCA2</it>. Ovarian cancer risk to 70 and to 80 years was 60% (95%CI 65–71%) and 65% (95%CI 75–84%) for <it>BRCA1 </it>and 30% (95%CI 25.5–34.5%) and 37% (95%CI 31.5–42.5%) for <it>BRCA2</it>. These risks were borne out by a prospective study of cancer in the families and genetic testing of unaffected relatives. We also found evidence of a strong cohort effect with women born after 1940 having a cumulative risk of 22% for breast cancer by 40 years of age compared to 8% in women born before 1930 (p = 0.0005).</p> <p>Conclusion</p> <p>In high-risk families, selected in a genetics service setting, women who test positive for the familial <it>BRCA1/BRCA2 </it>mutation are likely to have cumulative breast cancer risks in keeping with the estimates obtained originally from large families. This is particularly true for women born after 1940.</p>
url http://www.biomedcentral.com/1471-2407/8/155
work_keys_str_mv AT lalloofiona penetranceestimatesforitbrca1itanditbrca2itbasedongenetictestinginaclinicalcancergeneticsservicesettingrisksofbreastovariancancerquotedshouldreflectthecancerburdeninthefamily
AT woodwardemma penetranceestimatesforitbrca1itanditbrca2itbasedongenetictestinginaclinicalcancergeneticsservicesettingrisksofbreastovariancancerquotedshouldreflectthecancerburdeninthefamily
AT shentonandrew penetranceestimatesforitbrca1itanditbrca2itbasedongenetictestinginaclinicalcancergeneticsservicesettingrisksofbreastovariancancerquotedshouldreflectthecancerburdeninthefamily
AT evansdgareth penetranceestimatesforitbrca1itanditbrca2itbasedongenetictestinginaclinicalcancergeneticsservicesettingrisksofbreastovariancancerquotedshouldreflectthecancerburdeninthefamily
AT howellanthony penetranceestimatesforitbrca1itanditbrca2itbasedongenetictestinginaclinicalcancergeneticsservicesettingrisksofbreastovariancancerquotedshouldreflectthecancerburdeninthefamily
AT mahereamonnr penetranceestimatesforitbrca1itanditbrca2itbasedongenetictestinginaclinicalcancergeneticsservicesettingrisksofbreastovariancancerquotedshouldreflectthecancerburdeninthefamily
_version_ 1725476424197865472